



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/395, 38/00, C07D 521/00, C07K 5/12</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/17275 (43) International Publication Date: 30 April 1998 (30.04.98)</p>
<p>(21) International Application Number: PCT/US97/19210 (22) International Filing Date: 24 October 1997 (24.10.97) (30) Priority Data: 60/029,112 24 October 1996 (24.10.96) US (71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS [US/US]; 349 Administration Building University of Illinois, 506 South Wright Street, Urbana, IL 61801 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RINEHART, Kenneth, L. [US/US]; 454 Roger Adams Lab, 600 South Matthew Avenue, Urbana, IL 61801-3792 (US). KATAUSKAS, Alexandra, J. [US/US]; 454 Roger Adams Lab, 600 South Matthews Avenue, Urbana, IL 61801-3792 (US). (74) Agents: LINEK, Ernest, V. et al.; Dike, Bronstein, Roberts & Cushman, LLP, 130 Water Street, Boston, MA 02109-4280 (US).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>
<p>(54) Title: SEMI-SYNTHETIC STUDIES TOWARD DIDEMNIN ANALOGUES</p> <div data-bbox="289 1129 1255 1543"> </div> <p>(57) Abstract</p> <p>Disclosed are semi-synthetic methods for the preparation of Didemnin analogs. The compounds of this type are illustrated in Formula (I).</p>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Semi-Synthetic Studies Toward Didemnins Analogues


SUMMARY OF THE INVENTION

The syntheses of several didemnin derivatives, including didemnin M (1) as well as pyroglutamyl didemnin B (2), have been performed. Didemnin M, one of the most active of the didemnins, contains pyroglutamate, glutamine, lactyl, and proline groups in its side chain, while pyroglutamyl didemnin B contains only a pyroglutamyl unit in addition to the lactyl and prolyl residues. Glutamyl derivatives (3-5) were also synthesized in the process of producing didemnin M.




The retrosynthetic disconnections which formed the basis of a plan for preparation of the side chain of didemnin M are shown in Equation 1. Disconnection of the ester function between lactic acid and L-glutamine would give two units: a dipeptide, unit 7, comprised of pyroglutamate and glutamine; and unit 8, comprised of lactic acid and proline.

Equation 1




A mixed anhydride from L-pyroglutamic acid **9** and pivaloyl chloride was coupled with L-glutamine *t*-butyl ester **10** followed by acidic workup to yield L-pyroglutamyl-L-glutamine **7** (Equation 2). This dipeptide was purified by reversed phase HPLC using a gradient system of acetonitrile/H₂O.

Equation 2




The synthesis of compound 8 began with protection of (*S*)-ethyl lactate, 11, as the benzyloxy derivative 12. Hydrolysis provided the acid 13 which was coupled with L-proline phenacyl ester to afford compound 14. Treatment with a solution of zinc in acetic acid afforded 8 (Scheme I).

Scheme I




Didemnin M was synthesized by a three step scheme involving a coupling reaction of benzyl lactylproline, 8, with didemnin A to give the protected derivative 15 followed by hydrogenation to yield didemnin B. The final step involved coupling of the pyroglutaminyllutamine unit, 7, with didemnin B. This was carried out using a variety of techniques with the most efficient being the mixed anhydride method (Scheme II). Purification was performed using HPLC with an acetonitrile/H₂O gradient system.

Scheme II



A second approach toward the synthesis of didemnin M involved protecting L-glutamine, 16, as the benzyloxycarbonyl derivative, 17, followed by coupling with didemnin B using DCC. During this coupling procedure, two glutaminyl derivatives were produced, 18, bore a glutaminyl residue at only the lactyl residue while the second, 19, contained two glutaminyl residues, one on the lactyl unit and the second on the isostatine unit. These derivatives were separated via reversed phase HPLC, then hydrogenated to provide the deprotected compounds 3 and 4 (Scheme III).


Scheme III



- 4 -


A different attempt at deprotection of the benzyloxycarbonyl derivative **18** provided yet another glutaminyldidemnin analogue. This analogue was formed upon treatment of **18** with hydrogen bromide in acetic acid. It appears as though an acetyl unit was added to the isostatine residue to provide compound **5** (Equation 3). These two compounds appear to be easily separable by reversed phase HPLC. This deprotection technique also proved to be useful with the dibenzyloxycarbonylglutaminyldidemnin derivative of didemnin B, **19**.

Equation 3



Pyroglutamic acid was protected as the benzyloxycarbonyl derivative (**20**) which was then coupled with glutaminyldidemnin B (**3**) using DCC to provide the protected form of didemnin M (**21**). Deprotection via hydrogenation afforded didemnin M (**1**) (Scheme IV). Purification via reversed phase HPLC provided the desired compound.


Scheme IV



Another interesting analogue of didemnin is pyroglutaminyldidemnin B (**2**). The synthesis of **2** was accomplished by coupling **20** to didemnin B using EDC to provide Cbz-pyroglutaminyldidemnin B (**22**). Removal of the protecting group was accomplished using hydrogenation in the presence of a


palladium catalyst to afford 2. Purification via reversed phase HPLC, using an acetonitrile/water gradient system, provided the pure compound (Equation 4).

Equation 4



Dehydrodidemnin B was synthesized by first coupling Boc-L-proline (23) to didemnin A using EDC as the coupling agent. The Boc protecting group was removed upon treatment with acid and the resulting compound (25) was coupled with pyruvic acid to provide dehydrodidemnin B (Scheme V). The compound was purified via reversed phase HPLC using a gradient system of acetonitrile/H₂O.

Scheme V



DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

General Experimental Procedures. ¹H NMR spectra were recorded on Varian XL-200, General Electric QE-300, Varian XL-400, and General Electric QN-500 spectrometers. ¹H Chemical shifts are referenced in CDCl₃ and methanol-*d*₄ to residual CHCl₃ (7.26 ppm) and CD₂HOD (3.34 ppm). Electron impact (EI) mass spectra were recorded on a Finnigan MAT CH-5 DF spectrometer. High resolution (HRFAB) and fast atom bombardment (FAB) mass spectra were recorded on a VG ZAB-SE mass spectrometer operating in the FAB mode using magic bullet matrix.²⁷ Microanalytical results were obtained from the School of Chemical Sciences Microanalytical Laboratory. Infrared (IR) spectra

were obtained on an IR/32 FTIR spectrophotometer. Solid samples were analyzed as chloroform solutions in sodium chloride cells. Liquids or oils were analyzed as neat films between sodium chloride plates.

Optical rotations (in degrees) were measured with a DIP 360 or a DIP 370 digital polarimeter with an Na lamp (589 nm) using a 5- x 0.35-cm (1.0 mL) cell. Melting points were determined on a capillary melting point apparatus and are not corrected. Normal phase column chromatography was performed using Merck-kieselgel silica gel (70 - 230 mesh). Fuji-Davison C18 gel (100 - 200 mesh) was used for reversed phase column chromatography. All solvents were spectral grade. Analytical thin layer chromatography was performed on precoated plates (Merck, F-254 indicator). These plates were developed by various methods including exposure to ninhydrin, iodine, and UV light (254 nm). HPLC was performed with a Waters 990 instrument and an Econosil C18 column (Alltech/Applied Science) and a Phenomenex C18 column.

THF was distilled from sodium benzophenone ketyl and CH_2Cl_2 from P_2O_5 . Dimethylformamide (DMF), triethylamine (Et_3N), and *N*-methylmorpholine (NMM) were distilled from calcium hydride and stored over KOH pellets. Pyridine was distilled from KOH and stored over molecular sieves. Other solvents used in reactions were reagent grade without purification. Di-*tert*-butyl dicarbonate $[(\text{Boc})_2\text{O}]$, dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), dimethylaminopyridine (DMAP), 1-hydroxybenzotriazole (HOBT), L-glutamine, L-pyroglutamine, and L-proline were obtained from the Aldrich Chemical Company. All reactions requiring anhydrous conditions were performed under an atmosphere of nitrogen.

Pyroglutaminylglutamine (7). Pyroglutamic acid (0.11 g, 0.84 mmol) was dissolved in DMF (2.09 mL) and the solution was cooled to -20°C . *N*-Methylmorpholine (0.19 mL) and pivaloyl chloride (0.10 mL) were added to the solution and stirring continued at -20°C for 5 h. At this time, a solution of glutamine *t*-butyl ester (0.20 g, 0.84 mmol) in DMF (0.42 mL) and *N*-methylmorpholine (92 mL) was added dropwise. Stirring was continued for 48 h, and the solution was allowed to warm to room temperature, then poured into H_2O and extracted with EtOAc. The EtOAc layer was washed with 1N

HCl and H₂O, then dried (Na₂SO₄), and the solvent was carefully removed below 40°C. A white solid was isolated. Recrystallization from ether/petroleum ether provided **7** as a white crystalline material (0.17 g, 79%); FABMS 258.1 (M + H); HRFABMS calcd for C₁₀H₁₅N₃O₅ (M + H) 258.1090, found 258.1091.

Ethyl (S)-O-Benzyl lactate (12). To a solution of ethyl (S)-lactate (2.36 g, 20.0 mmol) in THF (7.80 mL) was added sodium hydride (60% dispersion, 0.94 g, 24.0 mmol) portionwise, with cooling. Benzyl bromide (2.60 mL, 22.0 mmol) was then added via a dropping funnel. The reaction was allowed to stand at room temperature for 24 h. Ethyl acetate (70 mL) was slowly added to the reaction mixture, followed by water, to destroy the excess sodium hydride. The solution was then evaporated to dryness and the oily residue was partitioned between ether (30 mL) and water (60 mL). The ether layer was washed with aqueous sodium bicarbonate (5 mL) and brine. The solution was dried over sodium sulfate and the solvent evaporated to give an oily residue which crystallized overnight. Recrystallization of the crude product gave the compound as a white crystalline material (3.01g, 72%); FABMS *m/z* 209.1 (M + H), 181.2 (M - C₂H₄).

O-Benzyl lactic acid (13). To a cold solution of **12** (0.31 g, 1.49 mmol) in THF (14.9 mL) was added, dropwise, a cold 0.2 M lithium hydroxide solution (14.9 mL) during 10-min. Stirring continued for 3 h at ambient temperature, then the solution was concentrated to half its volume and washed with ether (2 X 15 mL). The combined ether layers were extracted with saturated NaHCO₃ (10 mL), and the aqueous layers were combined and acidified to pH 4 with 1 N potassium hydrogen sulfate. The acidified aqueous layer was extracted with ether (3 X 50 mL) and the combined ether extracts were dried (Na₂SO₄), filtered, and concentrated under reduced pressure, providing the corresponding acid an oil, which was used directly in the next step (0.21g, 80%); ¹H NMR (500 MHz, CDCl₃) δ 1.46 (3H, d), 4.05 (1H, q), 4.55 (2H, dd), 7.31 (5H, s), 11.36 (1H, s); FABMS 219.0 (M + K), 203.1 (M + Na), 181.2 (M + H); HRFABMS calcd for C₁₀H₁₂NaO₃ (M + Na) 203.0684, found 203.0686; *m/z* calcd for C₁₀H₁₃O₃ (M + H) 181.0865, found 181.0864.

Boc-L-Proline Phenacyl Ester. Boc-proline (1.00 g, 4.65 mmol) was dissolved in ethyl acetate (29.4 mL), triethylamine (0.46 g, 0.63 mL) and phenacyl bromide (0.93 g, 4.68 mmol) were added and,

within a few minutes, a precipitate formed. The mixture was stirred overnight, water and ether were added and the two layers separated. The organic layer was washed with 0.1N HCl, saturated sodium bicarbonate, and brine, then dried over MgSO₄. Evaporation of the solvent provided the desired compound (1.27 g, 83%); FABMS 334.2 (M + H), 234.1 (M + 2H - Boc), 667.3 (2M + H); HRFABMS calcd for C₁₈H₂₃NO₅ (M + H) 334.1654, found 334.1665.

L-Proline phenacyl ester. Boc-L-proline phenacyl ester (0.29 g, 0.87 mmol) was dissolved in EtOAc (25 mL) and a steady current of HCl was passed through the solution for approximately 40 min, when TLC analysis showed the deprotection to be complete. The solvent was evaporated to provide a white crystalline material. Recrystallization from petroleum ether gave clear crystals (0.19 g, 94%); FABMS 234.2 (M + H), 467.2 (2M + H); HRFABMS calcd for C₁₃H₁₆NO₃ (M + H) 234.1130, found 234.1129.

L-O-Benzyl lactyl-proline Phenacyl Ester (14). Proline phenacyl ester (0.19 g, 0.83 mmol) in CH₂Cl₂, DMAP (0.10 g, 0.83 mmol) and DCC (0.19 g, 0.96 mmol) were added at 0°C to a solution of 13 (0.15 g, 0.83 mmol). The solution was allowed to warm to room temperature and stirred for 12 h. Dicyclohexylurea was filtered and washed with ethyl acetate. The filtrate and washings were combined and washed with 10% citric acid, 5% sodium bicarbonate and water, dried over MgSO₄ and concentrated. The crude residue was purified by flash chromatography eluting with hexane and ethyl acetate (4:1) to obtain the product (0.19 g, 57%) as an orange oil; FABMS 396.2 (M + H); HRFABMS calcd for C₂₃H₂₆NO₅ (M + H) 396.1811, found 396.1812.

L-O-Benzyl lactyl-proline (8). Compound 14 (0.19 g, 0.48 mmol) was treated with Zn (0.96 g) in AcOH/ H₂O (70:30), the mixture was allowed to stir at rt overnight, Zn was filtered off using celite, and the solution was partitioned between ether and water. The organic layer was separated and dried over Na₂SO₄ to afford the desired compound (0.11 g, 86%); FABMS 278.1 (M + H).

O-Benzyl didemnin B (15). L-O-Benzyl lactyl-proline (33.0 mg, 0.13 mmol) in DMF (3 mL), DMAP (0.6 mg) and DCC (26.0 mg, 0.13 mmol) were added at 0°C to a solution of didemnin A (39.7 mg, 0.42 mmol). The solution was allowed to warm to room temperature and stirred for 12 h, dicyclohexylurea was filtered and washed with ethyl acetate. The filtrate and washings were combined

and washed with 10% citric acid, 5% sodium bicarbonate and water, and the extracts were dried over MgSO_4 and concentrated. The crude residue was purified by reversed phase HPLC using a gradient system of acetonitrile/ H_2O to provide the compound as a yellow powder (40.5 mg, 80%); ^1H NMR (500 MHz, CDCl_3), see Supplementary Material, S-1; FABMS 1241.2 (M + K), 1226.1 (M + Na), 1203.1 (M + H), see Supplementary Material, S-2; HRFABMS calcd for $\text{C}_{64}\text{H}_{96}\text{N}_7\text{O}_{15}$ (M + H) 1202.6964, found 1202.6964.

Didemninn B. Protected didemninn B (15, 40.5 mg, 33.7 μmol) was dissolved in isopropyl alcohol (5 mL), palladium on carbon (10%) catalyst (37.4 mg) was added and the solution was hydrogenated at room temperature and atmospheric pressure for 3 h, when TLC showed the reaction to be complete. The catalyst was filtered over celite and the solvent was evaporated to provide the desired compound as a white powder. Reversed phase HPLC (acetonitrile/ H_2O gradient system) revealed the compound to be pure, see Supplementary Material, S-3 (32.1 mg, 86%); ^1H NMR (500 MHz, CDCl_3), see Supplementary Material, S-4; FABMS 1134.5 (M + Na), 1112.5 (M + H), Supplementary Material, S-5; HRFABMS calcd for $\text{C}_{57}\text{H}_{90}\text{N}_7\text{O}_{15}$ (M + H) 1112.6495, found 1112.6491.

Pyroglutaminyl-glutaminyl-didemnn B [Didemninn M (1)]. Pyroglutaminylglutamine (3.42 mg, 14.4 μmol) was dissolved in DMF (36.0 μL) and the solution was cooled to - 20 °C. *N*-Methylmorpholine (3.27 μL) and pivaloyl chloride (1.72 μL) were added to the solution and stirring continued at - 20 °C for 5 h, when a solution of didemninn B (16.0 mg, 14.4 μmol) in CH_2Cl_2 (7.23 μL) and *N*-methylmorpholine (1.59 μL) was added dropwise. Stirring continued for 48 h, then the solution was allowed to warm to room temperature, and the mixture was poured into H_2O and extracted with EtOAc. The EtOAc layer was washed with 1N HCl and H_2O , dried (Na_2SO_4), and solvent was carefully removed below 40 °C. Reversed phase HPLC using a gradient system of acetonitrile/ H_2O afforded the desired compound, see Supplementary Material, S-6 (8.1 mg, 79%); ^1H NMR (500 MHz, CDCl_3), see Supplementary Material, S-7; FABMS m/z 1389.5 (M + K), 1374.5 (M + Na), 1351.6 (M + H), see Supplementary Material, S-8; HRFABMS m/z calcd for $\text{C}_{67}\text{H}_{103}\text{N}_{10}\text{O}_{19}$ (M + H) 1351.7401, found 1351.7406.

N-Benzylloxycarbonyl-L-glutamine (17). Glutamine (1.84 g, 12.62 mmol) was dissolved in 1 N NaOH (12.58 mL) and the solution was cooled to 0 °C and stirred for 30 min, when Na₂CO₃ (3.30 g) and benzyl chloroformate (4.38 mL) in dioxane (19.30 mL) were gradually added, in equal portions. Stirring continued at 0 °C for 1 h, then the solution was allowed to stir overnight at room temperature and was extracted with ethyl ether (2 X 20 mL). The aqueous solution was acidified with 2N HCl to pH 5 and extracted with ethyl acetate (3 X 50 mL), which was dried over sodium sulfate, and evaporated to give an oil which crystallized overnight. Recrystallization of the crude product gave a white crystalline material (3.07 g, 87%); FABMS 319.1 (M + K), 281.1 (M + H).

N-Benzylloxycarbonyl-L-glutaminyldidemnin B (18). To a solution of Cbz-glutamine (0.14 g, 0.55 mmol) in dry DMF (2.50 mL), DMAP (0.6 mg) and DCC (20.6 mg, 0.11 mmol) were added at 20 °C with stirring. Stirring continued at room temperature for 2 h and a solution of didemnin B (23.0 mg, 20.6 µmol) in DMF (2.50 mL) was added with stirring. The solution was stirred at room temperature for 24 h, diluted with CH₂Cl₂ and washed with 5 % NaHCO₃ and water to neutral pH. The solution was dried (Na₂SO₄) and evaporated to give a white solid which was purified by reversed phase HPLC using a gradient system of acetonitrile/water, see Supplementary Material, S-9 (51.3 mg, 34%); ¹H NMR (500 MHz, CDCl₃), see Supplementary Material, S-10; FABMS 1374.6 (M + H), see Supplementary Material, S-11; HRFABMS calcd for C₇₀H₁₀₄N₉O₁₉ (M + H) 1374.7448, found 1374.7446. A second derivative was also obtained from HPLC purification (see Supplementary Material, S-12) and was found to be di-(benzyloxycarbonyl)glutaminyldidemnin B (36.0 mg, 20%); ¹H NMR (500 MHz, CDCl₃), see Supplementary Material, S-13; FABMS 1637.2 (M + H), see Supplementary Material, S-14; HRFABMS calcd for C₈₃H₁₁₈N₁₁O₂₃ (M + H) 1636.8402, found 1636.8401.

Glutaminyldidemnin B (3). Compound 18 (25.1 mg, 18.2 µmol) was dissolved in isopropyl alcohol (1.00 mL) and 10% Pd/C catalyst (0.99 mg) was added. The solution was hydrogenated for 3 h. The catalyst was removed by filtration over celite and solvent was removed to afford 3 which was purified by reversed phase HPLC using a gradient system of acetonitrile/water (see Supplementary Material, S-15) (19.6 mg, 87%); ¹H NMR (500 MHz, CDCl₃), see Supplementary Material, S-16;

FABMS 1278.5 (M + K), 1262.6 (M + Na), 1240.7 (M + H), see Supplementary Material, S-17; HRFABMS calcd for C₆₂H₁₀₆N₁₁O₁₉ (M + H) 1240.7081, found 1240.7076.

Glutaminyl-glutaminyl-didemnin B (4). The procedure was identical to that described above for 3. Compound 4 was also prepared by treatment of 19 with hydrogen bromide in acetic acid; FABMS 1368.7 (M + H), see Supplementary Material, S-18; HRFABMS calcd for C₆₇H₁₀₆N₁₁O₁₉ (M + H) 1368.7666, found 1368.7680.

N-Benzylloxycarbonyl-L-pyroglutamine (20). L-Pyroglutamine (2.02 g, 13.83 mmol) was dissolved in 1 N NaOH (13.84 mL) and the solution was cooled to 0 °C. After 30 min stirring, Na₂CO₃ (3.63 g) and benzyl chloroformate (4.82 mL) in dioxane (21.23 mL) were gradually added, in equal portions. Stirring was continued at 0 °C for 1 h, then the solution was stirred overnight at room temperature and extracted with ethyl ether (2 X 20 mL). The aqueous solution was acidified with 2N HCl to pH 5, extracted with ethyl acetate (3 X 50 mL), dried over sodium sulfate, and evaporated to give an oil which crystallized overnight. Recrystallization of the crude product gave white crystalline material (2.86 g, 87%); FABMS 240.1 (M + H).

L-(N-Benzylloxycarbonyl-pyroglutaminyl)-L-glutaminyl-didemnin B (21). To a solution of Cbz-pyroglutamine (10.2 mg, 38.7 µmol) in dry DMF (0.18 mL), DMAP (0.22mg) and DCC (7.59 mg, 7.74 µmol) were added at 20 °C with stirring. Stirring continued at room temperature for 2 h and a solution of didemnin B (9.60 mg, 7.74 µmol) in DMF (2.50 mL) was added with stirring. The solution was stirred at room temperature for 24 h. The solution was diluted with CH₂Cl₂ and washed with 5 % NaHCO₃ and water to neutral pH. The solution was dried (Na₂SO₄) and solvent evaporated to give 21 as a white solid. The compound was purified by reversed phase HPLC using a gradient system of acetonitrile/water (see Supplementary Material, S-19) (5.19 mg, 46%); ¹H NMR (500 MHz, CDCl₃), see Supplementary Material, S-20; FABMS 1524.2 (M + K), 1509.1 (M + Na), 1485.8 (M + H), see Supplementary Material, S-21; HRFABMS calcd for C₇₅H₁₀₉N₁₀O₂₁ (M + H) 1485.7769, found 1485.7765.

L-Pyroglutaminyl-L-glutaminyl-didemnin B [Didemnin M (1)]. Compound 21 (2.12 mg, 1.40 µmol) was dissolved in isopropyl alcohol (1.00 mL) and 10% Pd/C catalyst (9.90 µg) was added. The

solution was hydrogenated for 3 h, catalyst was removed by filtration over celite and solvent was removed to afford the desired compound. The compound was purified by reversed phase HPLC using a gradient system of acetonitrile/water (see Supplementary Material, S-6) (1.66 mg, 88%); ^1H NMR (500 MHz, CDCl_3), see Supplementary Material, S-7; FABMS 1389.5 (M + K), 1374.5 (M + Na), 1351.6 (M + H), see Supplementary Material S-8; HRFABMS calcd for $\text{C}_{67}\text{H}_{103}\text{N}_{10}\text{O}_{19}$ (M + H) 1351.7401, found 1351.7406.

N-Benzoyloxycarbonyl-L-pyroglutaminyldidemnin B (22). DMAP (0.48 mg) and EDC (16.5 mg, 88.0 μmol) were added at 20°C with stirring to compound 20 (0.11 g, 0.44 mmol) in dry CH_2Cl_2 (2.00 mL). Stirring continued at room temperature for 2 h and a solution of didemnin B (9.20 mg, 8.24 μmol) in CH_2Cl_2 (2.00 mL) was added with stirring. The solution was stirred at room temperature for 24 h, diluted with CH_2Cl_2 and washed with 5 % NaHCO_3 and water to neutral pH. The solution was dried (Na_2SO_4) and the solvent evaporated to give the compound as a white solid. The compound was purified by reversed phase HPLC using a gradient system of acetonitrile/water (5.70 mg, 52%); FABMS 1356.7 (M + H), see Supplementary Material, S-22; HRFABMS calcd for $\text{C}_{70}\text{H}_{102}\text{N}_9\text{O}_{18}$ (M + H) 1356.7343, found 1356.7335.

L-Pyroglutaminyldidemnin B (2). Compound 22 (5.70 mg, 4.28 μmol) was dissolved in isopropyl alcohol (0.5 mL) and 10% Pd/C catalyst (0.25 mg) was added. The solution was hydrogenated for 5 h, catalyst was removed by filtration, and the solvent was removed to afford 22, which was purified by reversed phase HPLC using a gradient system of acetonitrile/water, see Supplementary Material, S-23 (4.28 mg, 82%); ^1H NMR (500 MHz, CDCl_3), see Supplementary Material, S-24; FABMS 1223.7 (M + H), see Supplementary Material, S-25; HRFABMS calcd for $\text{C}_{62}\text{H}_{95}\text{N}_8\text{O}_{17}$ (M + H) 1223.6815, found 1223.6811.

Boc-L-prolyldidemnin A (24). DMAP (0.75 mg) and EDC (11.5 mg, 60.0 μmol) were added at 20 °C with stirring to Boc-L-proline (23) (25.0 mg, 0.12 mmol) in dry CH_2Cl_2 (2.00 mL). Stirring continued at room temperature for 2 h and a solution of didemnin B (44.4 mg, 40.0 μmol) in CH_2Cl_2 (2.00 mL) was added with stirring. The solution was stirred at room temperature for 24 h. The solution was diluted with CH_2Cl_2 and washed with 5 % NaHCO_3 solution and water to neutral pH. The solution

was dried (Na_2SO_4) and the solvent evaporated to give the compound as a white solid (17.5 mg, 42%); FABMS 1140.6 (M + H), 1040.6 (M + 2H - Boc).

L-Prolyl-didemnin B (25). Compound 24 (15.1 mg, 13.2 μmol) was dissolved in 5N HCl in ethyl acetate. After 3 h stirring at room temperature, TLC analysis showed the deprotection to be complete. The solvent was evaporated to provide a white crystalline material (12.5 mg, 91%); FABMS 1040.6 (M + H), see Supplementary Material, S-26.

Dehydrodidemnin B. DMAP (0.16 mg) and DCC (2.62 mg, 12.8 μmol) were added at 20°C with stirring to a solution of pyruvic acid (2.61 mg, 29.7 μmol) in dry DMF (0.10 mL). Stirring continued at room temperature for 2 h and a solution of prolyl-didemnin A (10.3 mg, 9.90 μmol) in DMF (0.40 mL) was added with stirring. The solution was stirred at room temperature for 24 h, diluted with CH_2Cl_2 and washed with 5 % NaHCO_3 solution and water to neutral pH, then dried (Na_2SO_4) and the solvent evaporated to give the product as a white solid. The compound was purified by reversed phase HPLC using a gradient system of acetonitrile/water (see Supplementary Material, S-27) to give a white powdery substance; ^1H NMR (500 MHz, CDCl_3), see Supplementary Material, S-28; FABMS 1110.6 (M + H), see Supplementary Material, S-29; HRFABMS calcd for $\text{C}_{57}\text{H}_{88}\text{N}_7\text{O}_{15}$ (M + H) 1110.6338, found 1110.6334.

- 14 -

TABLE I - Antiviral Activities of Didemnins^a (# - New Compounds)

Compound	HSV/CV-1		
	ng/mL	Cytotoxicity ^b	Activity ^c
# Gln-Didemnin B	100	16	?
	50	16	?
	20	16	?
	10	0	+++
# Cbz-Gln-Didemnin B (161)	100	0	+
	50	0	+
	20	0	+
	10	0	-
Didemnin M (5)	100	16	?
	50	16	?
	20	0	+++
	10	0	+
# pGlu-Didemnin B (39)	100	16	?
	50	16	?
	20	0	+++
	10	0	+
# Cbz-pGlu-Didemnin B (145)	100	0	+
	50	0	+
	20	0	+
	10	0	-
# Gln[GlnIst ²]-Didemnin B (160)	100	0	+++
	50	0	+
	20	0	+
	10	0	+
# Cbz-Gln[Cbz-GlnIst ²]DB (162)	100	0	+++
	50	0	+
	20	0	+
	10	0	+

SUBSTITUTE SHEET (RULE 26)

- 15 -

TABLE I (Continued)

Compound	ng/mL	HSV/CV-1	
		Cytotoxicity ^b	Activity ^c
O-Bu-Didemnin B (140)	100	16	?
	50	9	+
	20	8	+
	10	0	+
Didemnin (B) (2)	100	16	?
	50	0	+++
	20	0	+++
	10	0	+
Dehydroididemnin B (6)	100	16	?
	50	16	?
	20	0	+++
	10	0	+
Didemnin A (1)	100	0	+
	50	0	+
	20	0	+
	10	0	-

FOOTNOTES: ^a Performed by Dr. G. R. Wilson in this laboratory; ^b 0 (least toxic) to 16 (toxic); ^c +++ = complete inhibition; ++ = strong inhibition; + = moderate inhibition; - = no inhibition.

TABLE III - T/C (% of Control, Life Extension) vs. P388

Murine Leukemia in Mice		
#Gln-DB	T/C	Dose, mg/kg
	185	1
	171	0.05
	152	0.025

SUBSTITUTE SHEET (RULE 26)

TABLE II
Cytotoxicity of Didemnins^a # = New Compounds

Compounds	Dose (ng/mL)			Inhibition (%)	IC ₅₀ (ng/mL)
	250	25	2.5		
# Gln-Didemnin B (141)	100	100	100	94	0.1
# PGlu-Didemnin B (39)	100	100	100	94	0.1
Dehydrodidemnin B (6)	100	100	100	95	0.2
Didemnin M (6)	100	100	100	94	0.8
Didemnin B (2)	100	100	40	0	7
O-Bu-didemnin B (140)	100	97	0	NT ^b	10
Prolyl-didemnin A (43)	100	99	40	30	12
Cbz-Gln-didemnin B (161)	100	87	0	0	25
(Cbz-Gln) ₂ -didemnin B (162)	99	87	0	0	50
(Gln) ₂ -didemnin B (160)	100	87	0	0	50
Cbz-pGlu-didemnin B (145)	100	70	0	0	50
Didemnin A (1)	100	70	0	0	75
Boc-Pro-didemnin A (158)	100	55	0	0	85

^aPerformed by Dr. G.R. Wilson in this laboratory. ^bNT = not tested.

Table III. T/C (% of Control, Life Extension) vs. P388

Murine Leukemia in Mice

# Gln-DB	<u>T/C</u>	<u>Dose, mg/Kg</u>
	185	1
	171	0.05
	152	0.025

- 17/1 -

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a ^1H NMR spectrum of O-Benzylidemnin B (15). **Figure 2** is a LRFAB mass spectrum of O-Benzylidemnin B (15). **Figure 3** is a RPHPLC trace of Didemnin B. **Figure 4** is a ^1H NMR spectrum of Didemnin B. **Figure 5** is a LRFAB mass spectrum of O-Benzylidemnin B (15). **Figure 6** is a RPHPLC trace of Didemnin M (1). **Figure 7** is a ^1H NMR spectrum of Didemnin M (1). **Figure 8** is a LRFAB mass spectrum of Didemnin M (1). **Figure 9** is a RPHPLC trace of Benzyloxycarbonyl-L-Glutaminyldidemnin B (18). **Figure 10** is a ^1H NMR spectrum of Benzyloxycarbonyl-L-Glutaminyldidemnin B (18). **Figure 11** is a LRFAB mass spectrum of Benzyloxycarbonyl-L-Glutaminyldidemnin B (18). **Figure 12** is a RPHPLC trace of (Benzyloxycarbonyl-L-Glutaminy)₂-Didemnin M B(19). **Figure 13** is a ^1H NMR spectrum of (Benzyloxycarbonyl-L-Glutaminy)₂-Didemnin M B(19). **Figure 14** is a LRFAB mass spectrum of (Benzyloxy-carbonyl-L-Glutaminy)₂-Didemnin M B(19). **Figure 15** is a RPHPLC trace of Glutaminyldidemnin B (3). **Figure 16** is a ^1H NMR spectrum of Glutaminyldidemnin B (3). **Figure 17** is a LRFAB mass spectrum of Glutaminyldidemnin B (3). **Figure 18** is a LRFAB mass spectrum of Diglutaminyldidemnin B (4). **Figure 19** is a RPHPLC trace of Benzyloxycarbonyldidemnin M (21). **Figure 20** is a ^1H NMR spectrum of Benzyloxycarbonyldidemnin M (21). **Figure 21** is a LRFAB mass spectrum of Benzyloxycarbonyldidemnin M (21). **Figure 22** is a LRFAB mass spectrum of Benzyloxycarbonyl-L-Pyroglutaminyldidemnin B (22). **Figure 23** is a RPHPLC trace of Pyroglutaminyldidemnin B (23). **Figure 24** is a ^1H NMR spectrum of Pyroglutaminyldidemnin B (23). **Figure 25** is a LRFAB mass spectrum of Pyroglutaminyldidemnin B (23). **Figure 26** is a LRFAB mass spectrum of Prolyldidemnin A (25). **Figure 27** is a RPHPLC trace of Dehydrodidemnin B. **Figure 28** is a ^1H NMR spectrum of Dehydrodidemnin B. **Figure 29** is a LRFAB mass spectrum of Dehydrodidemnin B.

WHAT IS CLAIMED IS:

1. The compound Gln-Didemnin B.
2. A pharmaceutical composition comprising the compound Gln-Didemnin B and an optional pharmaceutically acceptable excipient, diluent or carrier.
3. The compound Cbz-Gln-Didemnin B.
4. A pharmaceutical composition comprising the compound Cbz-Gln-Didemnin B and an optional pharmaceutically acceptable excipient, diluent or carrier.
5. The compound pGlu-Didemnin B.
6. A pharmaceutical composition comprising the compound pGlu-Didemnin B and an optional pharmaceutically acceptable excipient, diluent or carrier.
7. The compound Cbz-pGlu-Didemnin B.
8. A pharmaceutical composition comprising the compound Cbz-pGlu-Didemnin B and an optional pharmaceutically acceptable excipient, diluent or carrier.
9. The compound Gln[GlnIst²]-Didemnin B.
10. A pharmaceutical composition comprising the compound Gln[GlnIst²]-Didemnin B and an optional pharmaceutically acceptable

excipient, diluent or carrier.

11. The compound Cbz-Gln[Cbz-GlnIst²]-Didemnin B.

12. A pharmaceutical composition comprising the compound Cbz-Gln[Cbz-GlnIst²]-Didemnin B and an optional pharmaceutically acceptable excipient, diluent or carrier.

13. A synthetic process for the preparation of Didemnin M comprising the step of coupling the pyroglutaminyglutamine compound (7) with Didemnin B to afford Didemnin M.

14. A synthetic process for the preparation of Didemnin M comprising the steps of:

- (a) coupling o-benzyl lactylproline (8) with Didemnin A to yield a protected derivative (15);
- (b) hydrogenation of derivative (15) to afford Didemnin B; and
- (c) coupling the pyroglutaminyglutamine compound (7) with Didemnin B to afford Didemnin M.

15. A method of treating mammalian neoplastic tumors comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition defined in claim 2, 4, 6, 8, 10 or 12.

16. A method of treating mammalian RNA or DNA viral infections comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition defined in claim 2, 4, 6, 8, 10 or 12.

17. A method of treating mammalian bacterial infections comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition defined in claim 2, 4, 6,

8, 10 or 12.

18. A method of treating mammalian fungal infections comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition defined in claim 2, 4, 6, 8, 10 or 12.

19. A method of promoting immunosuppression in mammals comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition defined in claim 2, 4, 6, 8, 10 or 12.

1/29





FIG. 1

2/29

FIG. 2



3/29




FIG. 3

4/29




FIG. 4

5/29




FIG. 5

6/29




FIG. 6

7/29




FIG. 7

8/29




FIG. 8

9/29




FIG. 9

10/29





FIG. 10

11/29



SUBSTITUTE SHEET (RULE 26)

FIG. 11

12/29




FIG. 12

13/29





FIG. 13

14/29



SUBSTITUTE SHEET (RULE 26)

FIG. 14

15/29




FIG. 15

SUBSTITUTE SHEET (RULE 26)

16/29





FIG. 16


17/29

FIG. 17



SUBSTITUTE SHEET (RULE 26)

18/29



SUBSTITUTE SHEET (RULE 26)

FIG. 18

19/29




FIG. 19

SUBSTITUTE SHEET (RULE 26)

20/29





FIG. 20

21/29




SUBSTITUTE SHEET (RULE 26)

FIG. 21

22/29

FIG. 22



SUBSTITUTE SHEET (RULE 26)

23/29




FIG. 23

SUBSTITUTE SHEET (RULE 26)

24/29





FIG. 24


25/29



SUBSTITUTE SHEET (RULE 26)

FIG. 25

26/29



SUBSTITUTE SHEET (RULE 26)

FIG. 26

27/29




FIG. 27

SUBSTITUTE SHEET (RULE 26)

28/29





FIG. 28

29/29




SUBSTITUTE SHEET (RULE 26)

FIG. 29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19210

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 31/395, 38/00; C07D 521/00; C07K 5/12 US CL :514/10, 11, 183; 530/317; 540/455 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/10, 11, 183; 530/317; 540/455 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, EPOABS, CAS ONLINE, MEDLINE, WPIDS, EMBASE, BIOSIS														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A	US 4,493,796 A (RINEHART, JR.) 15 January 1985, see entire document.	1-19												
A	US 4,948,791 A (RINEHART, JR. et al.) 14 August 1990, see entire document.	1-19												
A	US 5,294,603 A (RINEHART) 15 March 1994, see entire document.	1-19												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*E* earlier document published on or after the international filing date</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*A* document member of the same patent family</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 16 DECEMBER 1997		Date of mailing of the international search report 12 JAN 1998												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer BENNETT CELSA  Telephone No. (703) 308-0916												

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.